BTBeril Balci Topuz

Beril Balci Topuz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Beril Balci Topuz has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • REAL-WORLD OUTCOMES OF SECOND- AND THIRD-LINE THERAPIES AFTER FIRST-LINE VEGFR-TKI FAILURE IN METASTATIC RENAL CELL CARCINOMA: A SINGLE-CENTER EXPERIENCE FROM TÜRKİYE

    by Beril Balcı Topuz, Ahmet Tüfekçi, Sibel Cangi, Ömer Aydın Yıldırım, Mustafa Yıldırım

    Objective: Immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) have transformed the treatment of metastatic renal cell carcinoma (mRCC), yet access limitations continue to shape real-world practice. This study evaluated the outcomes of second- and third-line systemic therapies administered after TKI failure within a single-center cohort.Materials and methods: This retrospective study included 50 patients with histologically confirmed mRCC treated between 2014 and 2024. Eligible patients had received at least one line of TKI therapy and subsequently received second-line nivolumab or axitinib. Survival outcomes were analyzed using Kaplan – Meier and log-rank tests.Results: The median age was 63 years; 76% were International Metastatic RCC Database Consortium intermediate-risk, and 82% had undergone nephrectomy. First-line therapy consisted of sunitinib (72%) or pazopanib (28%), with a median progression-free survival (PFS) of 7 months. In the second line, 40 patients (80%) received nivolumab and 10 (20%) axitinib. Median PFS and OS were 10 and 20 months for nivolumab vs. 4 and 5 months for axitinib (both p0.05). Five patients (four axitinib and one cabozantinib) were alive at the last follow-up.Conclusion: In this cohort, nivolumab was associated with longer PFS and OS compared to axitinib in the second-line setting after TKI failure, whereas axitinib and cabozantinib demonstrated similar outcomes in the third-line setting.

  • Open Access

    CALLY index provides improved prognostic stratification compared with other inflammation-based scores in glioblastoma treated with the stupp protocol

    by Beril Balci Topuz, Meltem Ozturk Iyilikci

    Systemic inflammation and nutritional status are increasingly recognized as prognostic determinants in glioblastoma (GBM). The CRP–albumin–lymp


  • Open Access

    The C-Reactive Protein–Albumin–Lymphocyte (CALLY) Index as an Independent Predictor of Progression and Survival in Metastatic Renal Cell Carcinoma

    by Beril Balci Topuz, Ahmet Tufekci, Sibel Cangi, Omer Aydin Yildirim, Mustafa Yildirim

    Background/Objectives: Systemic inflammation, nutritional status, and immune competence have emerged as important prognostic determinants in metastatic renal cell carcinoma (mRCC). The C-reactive protein–albumin–lymphocyte (CALLY) index integrates these parameters into a single composite biomarker, yet its utility in mRCC remains insufficiently explored. This study aimed to evaluate the prognostic significance of the CALLY index in mRCC and its associations with clinicopathological features and survival outcomes. Methods: A total of 68 patients with mRCC treated between 2017 and 2024 were retrospectively analyzed. All patients received first-line VEGF–TKI therapy, and 73.5% subsequently received second-line treatment, predominantly nivolumab. The CALLY index was calculated as (albumin × lymphocyte count)/(CRP × 104), and patients were stratified using the median cut-off (0.16). Survival outcomes were assessed with Kaplan–Meier and Cox regression analyses. Discriminative performance was evaluated using Harrell’s C-index and time-dependent ROC curves at 6, 12, and 24 months. Results: Low CALLY (≤0.16) was significantly associated with shorter PFS (4 vs. 8 months, p < 0.001) and OS (9 vs. 26 months, p < 0.001). In multivariate analysis, the CALLY index independently predicted both PFS (HR = 1.91, p = 0.045) and OS (HR = 2.89, p = 0.005). Time-dependent ROC analysis demonstrated increasing discriminative strength for PFS (AUC: 0.70 → 0.95) and modest decline for OS over time (AUC: 0.83 → 0.72). CALLY also showed strong associations with IMDC risk classification and peritoneal metastasis. Conclusions: The CALLY index is a simple, cost-effective, and objective prognostic biomarker that may independently predict progression and survival in mRCC. Its complementary value to the IMDC model supports its integration into routine risk stratification and real-world clinical decision-making.


  • Open Access

    Prognostic value of early treatment response to craniospinal irradiation in diffuse leptomeningeal glioneuronal tumors: a case series

    by Beril Balcı Topuz, Tuğçe Bozkurt Vardar, Meltem Öztürk İyIlikci, Cenk Eraslan, Eda Ataseven, Elif Bolat, Yeşim Ertan, Taner Akalın, Serra Kamer

    Background. Diffuse leptomeningeal glioneuronal tumors (DLGNTs) are rare pediatric central nervous system neoplasms with poorly defined treatment strategies and prognostic factors. Although chemotherapy (CHT) is frequently used, the role of radiotherapy (RT), particularly craniospinal irradiation (CSI), remains unclear. Case Presentations. We present a case series of three pediatric patients diagnosed with DLGNTs and treated with CSI at an initial dose of 36 Gy, with an additional boost to 54 Gy. Patients were evaluated for early radiological response post-CSI and its potential prognostic implications, alongside their clinical and histological features. Two patients demonstrated significant radiological regression after 36 Gy of CSI, with continued improvement 1.5 months post-treatment. These patients remained stable for 88 and 27 months, respectively, without further disease progression. The third patient exhibited disease progression despite CSI and concurrent temozolomide, ultimately succumbing to the disease within 10 months. Notably, this patient had a Ki-67/MIB-1 index of 70%, while surviving patients had lower proliferation indices. Conclusions. Our findings suggest that an early favorable response to 36 Gy of CSI may serve as a prognostic indicator in DLGNTs. This study highlights the potential value of CSI in managing these tumors and underscores the need for further research to establish standardized treatment approaches.

  • Open Access

    Aggressive Squamous Cell Carcinoma of Unknown Primary: Isolated Inguinal Metastasis and Uncommon Progression

    by Beril Balci Topuz, Mustafa Seyyar, Meltem Ozturk Iyilikci, Gozde Ertunc, Elif Yumuk, Evren Uzun

    BACKGROUND Carcinoma of unknown primary (CUP) is a rare malignancy, accounting for less than 5% of all cancers. Inguinal lymph node (LN) metastasis is an uncommon presentation, with squamous cell carcinoma (SCC) comprising a small subset of CUP cases. CASE REPORT A 65-year-old woman presented with a left inguinal mass, which was confirmed as SCC. Comprehensive diagnostics, including PET-CT, failed to identify a primary tumor. Following initial surgical resection, she experienced local recurrence and was treated with chemoradiotherapy (CRT), receiving 45 Gy to potential primary and nodal sites, followed by a 59.4 Gy boost and concurrent cisplatin. Despite an initial response to treatment, the disease progressed aggressively, leading to lung metastases and a subcutaneous metastatic nodule in the pubic region. After chemotherapy with cisplatin and 5-fluorouracil, 2 nodular lesions were identified in the right breast as new metastases - a finding not previously documented in the literature. Despite plans for a biopsy of the right breast lesions, the patient died due to respiratory complications 12 months after diagnosis. CONCLUSIONS This case of isolated inguinal LN metastasis from SCC of an unknown primary highlights the unpredictable and aggressive nature of CUP, even in subtypes typically considered favorable. The findings suggest that more aggressive multimodal treatment approaches may be warranted to manage and control potential microscopic disease effectively. Reevaluating standard treatment protocols for such presentations is essential to improve patient outcomes.


  • Open Access

    HPV status and immunohistochemical analysis of p16, p53 and PD‑L1 expression as prognostic biomarkers in patients with squamous cell anal cancer receiving definitive radiotherapy/chemoradiotherapy

    by Beril Balci Topuz, Fatma Sert, Murat Sezak, Mehmet Soylu, Deniz Yalman, Serdar Ozkok

    Anal squamous cell carcinoma (SCC) treated with definitive radiotherapy (RT)/chemoradiotherapy (CRT) has shown high success rates, yet challenges such as treatment resistance and recurrence persist. The present study aimed to investigate the associations between immunohistochemical (IHC) evaluation, treatment response and prognosis in anal SCC. A retrospective cohort analysis included 42 patients with anal SCC treated at a single institution between 2006 and 2022. Human papillomavirus (HPV) status was determined, and the IHC analysis of p16, p53 and PD‑L1 expression was conducted using formalin‑fixed, paraffin‑embedded biopsies. A complete response to RT/CRT was observed in 71.4% of patients. Recurrence occurred in 38.1% of cases, of which 7.1% had local‑regional recurrence (LRR), 14.3% had distant recurrence (DR), and 16.7% had both LRR and DR. HPV positivity (71.4%) was significantly associated with p16 positivity. Lack of complete response was associated with HPV‑negative status, p16‑negative status, increased recurrence and DR. In addition, recurrence was significantly associated with p53‑positive status, and p53 positivity was significantly associated with increased LRR. PD‑L1 positivity, defined as a combined positive score (CPS) ≥1% was found in 73.8% of the patients, and exhibited significant associations with HPV positivity and p16 positivity. PD‑L1 CPS ≥ 1% was also associated with an increased LRR. Univariate analysis revealed that age <65 years, a complete response and HPV positivity were associated with increased 5‑year overall survival (OS), while a complete response, HPV positivity and p53‑negative status were associated with increased 5‑year disease‑free survival (DFS). Multivariate analysis identified that age <65 years and HPV positivity are independent prognostic factors for 5‑year OS, and a complete response and p53‑negative status are independent prognostic factors for 5‑year DFS. In conclusion, these findings suggust that the identification of HPV status and poor prognostic biomarkers at diagnosis may be used to guide personalized treatment strategies, with the combination of immunotherapy with standard CRT potentially providing improved outcomes.